Background: The detection of occult bone metastases is a key factor in determining the management of patients with renal cell carcinoma (RCC), especially when curative surgery is considered. This prospective study assessed the sensitivity of (18)F-labelled sodium fluoride in conjunction with positron emission tomography/computed tomography ((18)F-NaF PET/CT) for detecting RCC bone metastases, compared with conventional imaging by bone scintigraphy or CT.
Patients And Methods: An adaptive two-stage trial design was utilized, which was stopped after the first stage due to statistical efficacy. Ten patients with stage IV RCC and bone metastases were imaged with (18)F-NaF PET/CT and (99m)Tc-labelled methylene diphosphonate ((99m)Tc-MDP) bone scintigraphy including pelvic single photon emission computed tomography (SPECT). Images were reported independently by experienced radiologists and nuclear medicine physicians using a 5-point scoring system.
Results: Seventy-seven lesions were diagnosed as malignant: 100% were identified by (18)F-NaF PET/CT, 46% by CT and 29% by bone scintigraphy/SPECT. Standard-of-care imaging with CT and bone scintigraphy identified 65% of the metastases reported by (18)F-NaF PET/CT. On an individual patient basis, (18)F-NaF PET/CT detected more RCC metastases than (99m)Tc-MDP bone scintigraphy/SPECT or CT alone (P = 0.007). The metabolic volumes, mean and maximum standardized uptake values (SUV mean and SUV max) of the malignant lesions were significantly greater than those of the benign lesions (P < 0.001).
Conclusions: (18)F-NaF PET/CT is significantly more sensitive at detecting RCC skeletal metastases than conventional bone scintigraphy or CT. The detection of occult bone metastases could greatly alter patient management, particularly in the context when standard-of-care imaging is negative for skeletal metastases.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC4576907 | PMC |
| http://dx.doi.org/10.1093/annonc/mdv289 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Validation of quantitative [F]NaF PET uptake parameters in bone diseases: a systematic review.
Ann Nucl Med
December 2024
Department of Endocrinology and Metabolism, Rare Bone Disease Center, Amsterdam University Medical Centers (UMC), Vrije Universiteit, Amsterdam Movement Sciences, Amsterdam, The Netherlands.
Purpose: [F]NaF PET has become an increasingly important tool in clinical practice toward understanding and evaluating diseases and conditions in which bone metabolism is disrupted. Full kinetic analysis using nonlinear regression (NLR) with a two-tissue compartment model to determine the net rate of influx (K) of [F]NaF is considered the gold standard for quantification of [F]NaF uptake. However, dynamic scanning often is impractical in a clinical setting, leading to the development of simplified semi-quantitative parameters.
View Article and Find Full Text PDFSafety and Efficacy of Moderate-Dose Denosumab in Fibrous Dysplasia: Observational Results from a Phase 2 Clinical Trial.
J Clin Endocrinol Metab
December 2024
National Institute of Dental and Craniofacial Research, National Institutes of Health, Bethesda, MD, USA.
Context: Fibrous dysplasia (FD) is a rare skeletal mosaic disease associated with fractures and disability. A phase 2 trial of the RANKL inhibitor denosumab (NCT03571191) reported profound reductions in lesion activity and increased lesional mineralization after 6-months of high-dose treatment. Denosumab was well-tolerated, however discontinuation was associated with severe hypercalcemia.
View Article and Find Full Text PDFEstimating inflammatory risk in atherosclerotic cardiovascular disease: plaque over plasma?
Eur Heart J Cardiovasc Imaging
December 2024
Department of Vascular Medicine, Amsterdam UMC, University of Amsterdam, Amsterdam, the Netherlands.
Inflammation is an important driver of disease in the context of atherosclerosis, and several landmark trials have shown that targeting inflammatory pathways can reduce cardiovascular event rates. However, the high cost and potentially serious adverse effects of anti-inflammatory therapies necessitate more precise patient selection. Traditional biomarkers of inflammation, such as high-sensitivity C-reactive protein (hsCRP), show an association with cardiovascular risk on a population level, but do not have specificity for local plaque inflammation.
View Article and Find Full Text PDF18F-sodium fluoride positron emission tomography is a sensitive imaging technique to detect atherosclerosis in Amazon parrots (Amazona spp).
Am J Vet Res
December 2024
Department of Medicine and Epidemiology, School of Veterinary Medicine, University of California-Davis, Davis, CA.
Objective: To investigate and establish a protocol for 18F-sodium fluoride (18F-NaF) PET scan imaging in Amazon parrots for atherosclerosis diagnosis.
Methods: In this feasibility proof-of-concept study, 18F-NaF μPET scan and μCT scan were obtained on Hispaniolan (Amazona ventralis) and orange-winged Amazon parrots (A amazonica). A different μPET scan protocol was used for each species.
F-NaF uptake in skull-base bone as a predictor of treatment response in advanced nasopharyngeal carcinoma.
Sci Rep
November 2024
Department of Nuclear Medicine, Affiliated Hospital of Guilin Medical University, Guilin, 541001, Guangxi Zhuang Autonomous Region, People's Republic of China.
Article Synopsis
- This study examines how F-sodium fluoride (F-NaF) PET/CT scans can help assess skull-base bone invasion (SBBI) and predict treatment responses in advanced nasopharyngeal carcinoma (NPC).
- It analyzes data from 142 patients diagnosed with advanced NPC, showing that higher F-NaF uptake at the skull base is linked to more advanced disease stages and worse treatment outcomes.
- The findings suggest that F-NaF PET/CT may serve as an important prognostic tool, as lower uptake correlates with better treatment response.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!